ISM8969 / Insilico Medicine - LARVOL DELTA

Insilico Medicine Advances Parkinson’s Therapy with IND-Enabling Milestone for AI-Driven Oral NLRP3 Inhibitor ISM8969 (Bioengineered) - "This novel inhibitor has successfully completed Investigational New Drug (IND)-enabling studies, positioning ISM8969 to enter clinical trials as a potential transformative therapy for Parkinson’s disease (PD) in the fourth quarter of this year."

New trial • Parkinson's Disease